Going Concern and Management's Plans (Details) - USD ($)			1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 09, 2021	Feb. 11, 2021	Nov. 25, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Feb. 11, 2020
Conversion of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs					$ 5,477,432
Healthcare-focused Institutional Investor [Member] | February 2021 Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues		2,784,184
Gross proceeds from sale of common stock		$ 25,000,000
Proceeds from issuance of common stock, net of issuance costs		$ 23,500,000
Healthcare-focused Institutional Investor [Member] | February 2021 Offering [Member] | Pre Funded Warrant [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues		5,549,149
Sale of stock, description of transaction		Each pre-funded warrant exercisable for one share of common stock.
Investor [Member] | February 2021 Offering [Member]
Conversion of Stock [Line Items]
Offering of common stock and warrants		4,166,666
Shares issued, price per share		$ 3.00
Class of warrant or right, exercise price of warrants or rights		$ 3.55
Warrants exercisable period		6 months
Warrants expiry period		5 years 6 months
Investor [Member] | February 2021 Offering [Member] | Pre Funded Warrant [Member]
Conversion of Stock [Line Items]
Shares issued, price per share		$ 2.99
Class of warrant or right, exercise price of warrants or rights		$ 0.01
Healthcare-focused U.S. Institutional Investor [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues		2,784,184
Shares issued, price per share		$ 3.00
Gross proceeds from sale of common stock		$ 25,000,000
Proceeds from issuance of common stock, net of issuance costs		$ 23,400,000
Class of warrant or right, exercise price of warrants or rights		$ 0.01
Warrants exercisable period		6 months
Warrants expiry period		5 years 6 months
Healthcare-focused U.S. Institutional Investor [Member] | Pre Funded Warrant [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues		5,549,149
Shares issued, price per share		$ 2.99
Class of warrant or right, exercise price of warrants or rights		$ 3.55
Warrants exercised		4,166,666
Healthcare-focused U.S. Institutional Investor [Member] | 2020 PIPE [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues			2,245,400
Shares issued, price per share			$ 2.065
Gross proceeds from sale of common stock			$ 10,000,000
Proceeds from issuance of common stock, net of issuance costs			$ 9,300,000
Sale of stock, description of transaction			Eeach pre-funded warrant exercisable for one share of common stock.
Class of warrant or right, exercise price of warrants or rights			$ 1.94
Warrants exercisable period			6 months
Warrants exercised			4,842,615
Warrants expiry period			5 years 6 months
New warrants issue against outstanding warrants			2,245,400
Healthcare-focused U.S. Institutional Investor [Member] | 2020 PIPE [Member] | Pre Funded Warrant [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues			2,597,215			2,597,215
Shares issued, price per share			$ 2.055
Warrants exercised			2,597,215
New warrants issue against outstanding warrants			2,597,215
Warrant [Member] | Holder [Member] | Purchase Agreement [Member]
Conversion of Stock [Line Items]
Offering of common stock and warrants	4,842,615
Warrant [Member] | Holder [Member] | Exercise Agreement [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights	$ 3.56
Warrants expiry period	5 years
Number of warrants outstanding	4,842,615
Number of each warrant issue to purchase common stock	0.65
New warrants issue against outstanding warrants	3,147,700
Payment to purchase new warrants	$ 255,751
Description of expenses related to purchase warrants	The Company received aggregate gross proceeds before expenses of approximately $9.65 million from the exercise of all of the remaining 4,842,615 outstanding Existing Warrants held by the Holder
Warrant [Member] | Alliance Global Partners [Member] | Purchase Agreement [Member]
Conversion of Stock [Line Items]
Cash fee compensation	$ 200,000
Common Stock [Member] | H.C. Wainwright & Co., LLC [Member] | 2020 ATM Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues						7,521,610
Gross proceeds from sale of common stock						$ 16,700,000
Proceeds from issuance of common stock, net of issuance costs						$ 15,800,000
Common Stock [Member] | H.C. Wainwright & Co., LLC [Member] | 2020 ATM Offering [Member] | Maximum [Member]
Conversion of Stock [Line Items]
Common shares available for future issuance amount							$ 22,100,000